



ARTHROSAMID[®]
by **contura** Orthopaedics Ltd.

SAFE AND SUSTAINED PAIN RELIEF
WITH A SINGLE INJECTION¹

An estimated 5.6 million patients in the UK suffer with knee osteoarthritis (OA), but not all are suitable for surgery, creating a growing need for non-surgical treatments.²

Come and find out more about a new non-degradable viscoelastic hydrogel for adults with knee OA.



THE KNEE OA TREATMENT 20 YEARS IN THE MAKING

Inviting you to attend the Thought Leadership Session on:

Tuesday 21st September, BOA Conference Suite 4

17:45 - 18:00 Arrival with drinks reception

18:00 - 18:30 Presentations



Please register interest here
drinks will be available during the presentations

Agenda

- What are the limitations to treat the fastest growing cause of disabilities worldwide?
- The history of iPAAG – Novel therapy to treat patients with knee OA
- Years of experience in using iPAAG: the benefits I have seen in patients with knee OA

Invited Faculty



Professor Henning Bliddal

Rheumatologist
Parker Institute
Frederiksberg Hospital
Denmark



Ieva Ankorina-Stark

Chief Scientific Officer
Contura
UK



Mr Sean Curry

Consultant Orthopaedic and Trauma Surgeon
London Orthopaedic Clinic
King Edward VII Hospital
London, UK



Come visit us at


BOA Annual Congress 2021 (booth 23) if you have any questions.

Introducing ARTHROSAMID®

Intra-articular Polyacrylamide Hydrogel (iPAAG) a novel therapeutic concept. Arthrosamid® is a non-biodegradable single-dose injection that delivers long-acting pain relief, improving the quality of life for patients with knee osteoarthritis.^{1,3}

Polyacrylamide Hydrogel Injection for Knee Osteoarthritis


52 Week Prospective Study.^{1,3,4}



>70% of patients had a response larger than MCID[†] for all 3 WOMAC subscales at week 26.^{1,3}
Pain and physical function were maintained at 52 weeks⁴

Similar results were found for
OMERACT-OARSI and PGA scale^{1,3}

**WOMAC or The Western Ontario and McMaster Universities Osteoarthritis index is a measure of symptoms and physical disability
[†]MCID - Minimal Clinically Important Difference



iPAAG

Arthrosamid[®] is
safe
for intended use⁵

More than
700,000
hydrogel units have
been used for various
indications in the body

Undergone over
two decades
of research and
development⁶



@Conturaltd



Contura-orthopaedics-ltd

Further information is available at Arthrosamid.com or contact us to use Arthrosamid[®]
in your osteoarthritis knee patients at enquiries@arthrosamid.com.

www.Arthrosamid.com

1. Bliddal H, Overgaard A, Hartkopp A, Beier J, Conaghan PG, et al. (2021) Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: A 6 Months Prospective Study. J Orthop Res Ther 1188-6.

2. Future Market Insights Viscosupplementation Market Report 2020.

3. Bliddal H, Overgaard A, Hartkopp A, Beier J, Conaghan PG, et al. (2021) Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results of a 52 Week Prospective Study. Poster presented at OARS Connect 2021.

4. Data on file.

5. Overgaard, A., Bliddal, H., Henriksen, M., 2019. Safety of Intra-Articular Polyacrylamide Hydrogel for the Treatment of Knee Osteoarthritis Symptoms: A Retrospective Case Series. Clin Ortho Adv Res J. COARJ-1000001.

6. Arthrosamid. Information for Use. Release Date November 2020 10062-002.